Dong Geng

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · The Lancet · 2021 · 1.5K citations

Hematological Malignancy, Cell Therapy, Immunotherapy +11

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

Adam D. Cohen, Samir Parekh, Bianca Santomasso et al. · Blood Cancer Journal · 2022 · 235 citations · Full text

CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen-Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma

Deepu Madduri, Jesús G. Berdeja, Saad Z. Usmani et al. · Blood · 2020 · 92 citations

CAR+ T-Cell Lymphoma Post Ciltacabtagene Autoleucel Therapy for Relapsed Refractory Multiple Myeloma

Simon J. Harrison, Tamia Nguyen, Marzia Rahman et al. · Blood · 2023 · 91 citations

Update of CARTITUDE-1: A phase Ib/II study of JNJ-4528, a B-cell maturation antigen (BCMA)-directed CAR-T-cell therapy, in relapsed/refractory multiple myeloma.

Jesús G. Berdeja, Deepu Madduri, Saad Z. Usmani et al. · Journal of Clinical Oncology · 2020 · 78 citations

Clinical Immunology, Cell Therapy, Adaptive Immune System +24